Stockscreener 앱 받기
0.1856
2.54%
0.0046
시간 외 거래:
.18
-0.0056
-3.02%
전일 마감가:
$0.181
열려 있는:
$0.1797
하루 거래량:
1.46M
Relative Volume:
0.15
시가총액:
$6.62M
수익:
-
순이익/손실:
$-23.74M
주가수익비율:
-0.046
EPS:
-4.0366
순현금흐름:
$-16.70M
1주 성능:
+2.54%
1개월 성능:
-5.64%
6개월 성능:
-53.01%
1년 성능:
-84.14%
1일 변동 폭
$0.1771
$0.189
1주일 범위
$0.172
$0.2198
52주 변동 폭
$0.1628
$1.50
Theriva Biologics Inc Stock (TOVX) Company Profile
명칭
Theriva Biologics Inc
전화
301 417 4364
주소
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.1856 | 6.46M | 0 | -23.74M | -16.70M | -4.0366 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Aug Swings: Will Theriva Biologics Inc outperform its industry peers2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
Theriva Biologics (NYSE: TOVX) puts 16.2M warrant share issuance to vote - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget
TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus
Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView
Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView
Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider
Theriva Biologics (NYSE: TOVX) details 2025 loss and cash runway into 2027 - Stock Titan
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - The Manila Times
Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan
Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Shorts: Can Theriva Biologics Inc maintain sales growthAnalyst Upgrade & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits
TOVX Should I Buy - Intellectia AI
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits
TOVX Technical Analysis & ETF Price Forecast - Intellectia AI
Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.
Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com
Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView
Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks
Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget
How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru
Published on: 2026-02-14 06:14:36 - mfd.ru
Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail
How Theriva Biologics Inc. stock correlates with oil marketsM&A Rumor & Comprehensive Market Scan Insights - mfd.ru
Will Theriva Biologics Inc. outperform its industry peersWeekly Stock Report & Low Drawdown Trading Strategies - mfd.ru
Theriva Biologics Reschedules Stockholder Meeting - TradingView
Theriva Biologics (NYSE: TOVX) to reschedule vote on 16.18M warrant shares - Stock Titan
Death Cross: Can Theriva Biologics Inc. grow without dilutionJuly 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Published on: 2026-02-09 23:08:24 - mfd.ru
Analyst Downgrade: Why is Theriva Biologics Inc stock going downJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Bond Watch: Is Theriva Biologics Inc. subject to activist investor interest2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire
Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan
Street Watch: Is Theriva Biologics Inc showing insider buyingWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Theriva Biologics Inc backed by strong institutional buyingJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? - Defense World
Dow Update: Can Theriva Biologics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Theriva Biologics Inc continue delivering strong returnsQuarterly Portfolio Summary & Long-Term Growth Plans - baoquankhu1.vn
Theriva Biologics advances VCN-01 toward Phase 3 trial - TipRanks
How Theriva Biologics Inc. stock performs in rate cut cyclesProfit Target & Consistent Growth Equity Picks - Улправда
How Theriva Biologics Inc. stock reacts to fiscal policiesPortfolio Return Summary & AI Forecasted Entry/Exit Points - Улправда
Will Theriva Biologics Inc. stock profit from fiscal stimulusJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - Улправда
Theriva Biologics Inc (TOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):